Patients
58 % of married women 15–49
Contraception use, Japan, 2021 (WHO).
Compare every country on the Public Health Dashboard
Updated
Reviewed by Vidhi Upadhyay
Japan Contraceptive Innovations Market Industry Trends and Forecast to 2034: Segmented by (Product, Hormone, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$188.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $247.6 Mn | — | — |
| 2025 (base) | $262.9 Mn | +$15.3 Mn | — |
| 2026 (forecast) | $279.2 Mn | +$16.3 Mn | +6.2% |
| 2027 (forecast) | $296.5 Mn | +$17.3 Mn | +12.8% |
| 2028 (forecast) | $314.9 Mn | +$18.4 Mn | +19.8% |
| 2029 (forecast) | $334.4 Mn | +$19.5 Mn | +27.2% |
| 2030 (forecast) | $355.2 Mn | +$20.7 Mn | +35.1% |
| 2031 (forecast) | $377.2 Mn | +$22.0 Mn | +43.5% |
| 2032 (forecast) | $400.6 Mn | +$23.4 Mn | +52.4% |
| 2033 (forecast) | $425.4 Mn | +$24.8 Mn | +61.8% |
| 2034 (forecast) | $451.8 Mn | +$26.4 Mn | +71.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $262.9 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $451.8 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 6.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product, hormone and end user (see all) |
| Key players | Bayer AG, Organon, Perrigo Company plc, Evofem Biosciences, Mithra Pharmaceuticals and 1 more (see all) |
| Regulator in Japan | PMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Contraceptive innovations are newer birth-control options such as hormone-free gels, long-acting injectables, vaginal rings and over-the-counter pills.
Key segments of the contraceptive Innovations market include product (Over-the-Counter Pills, Long-Acting Injectables and Vaginal Rings) and hormone (Hormonal and Non-Hormonal).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the contraceptive Innovations market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the contraceptive Innovations market.
The contraceptive Innovations market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).[2] Contraception use: 58% of married women 15–49 in 2021, the latest WHO figure for Japan.[3]
[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[3] WHO Global Health Observatory, Contraception use (% of married women 15–49). Retrieved 15 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for contraceptive Innovations. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.
What doctors and scientists are doing in Contraceptive Innovations right now, from free public sources.
58 % of married women 15–49
Contraception use, Japan, 2021 (WHO).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Contraception use (% of married women 15–49). Retrieved 15 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.
From our blog
Japan · 1 shared keyword
Japan · 1 shared keyword
Japan
Japan
Japan
Japan
Healthcare Services · Japan
Medical Devices · Japan
Healthcare Services · Japan
Digital Health · Japan
Healthcare Services · Japan
Healthcare Services · Japan